STOCK TITAN
  1. Home
  2. Sec-filings
  3. ONC
  4. [Form 4] BeOne Medicines Ltd. Insider Trading Activity

ONC President & COO reports ADS insider sales around $380 per share

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) reported an insider transaction by its President and COO on a Form 4. The executive is listed as directly holding 968,978 ordinary shares and indirectly holding 4,000 American Depositary Shares (ADS) through his wife. Each ADS represents 13 ordinary shares.

On 11/17/2025, the reporting person sold ADS in three open-market transactions: 3,155 ADS at a weighted average price of $380.2274, 826 ADS at a weighted average price of $381.1891, and 10 ADS at $382.32. After these sales, the Form 4 shows reduced direct ADS holdings, while the separate ordinary share and spouse-held ADS positions remain reported.

Positive

  • None.

Negative

  • None.
Insider Wu Xiaobin
Role President and COO
Sold 3,991 shs ($1.52M)
Type Security Shares Price Value
Sale American Depositary Shares 3,155 $380.2274 $1.20M
Sale American Depositary Shares 826 $381.1891 $315K
Sale American Depositary Shares 10 $382.32 $4K
holding Ordinary Shares -- -- --
holding American Depositary Shares -- -- --
holding American Depositary Shares -- -- --
Holdings After Transaction: American Depositary Shares — 836 shares (Direct); Ordinary Shares — 968,978 shares (Direct); American Depositary Shares — 4,000 shares (Indirect, By Wife)
Footnotes (1)
  1. Each American Depositary Share represents 13 Ordinary Shares. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $380.00 to $380.765, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $381.115 to $381.88, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wu Xiaobin
(Last) (First) (Middle)
C/O BEONE MEDICINES I GMBH
AESCHENGRABEN 27, 21ST FLOOR
(Street)
BASEL V8 4051
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 968,978 D
American Depositary Shares(1) 12,365 D
American Depositary Shares(1) 4,000 I By Wife
American Depositary Shares(1) 11/17/2025 S 3,155 D $380.2274(2) 836 D
American Depositary Shares(1) 11/17/2025 S 826 D $381.1891(3) 10 D
American Depositary Shares(1) 11/17/2025 S 10 D $382.32 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Each American Depositary Share represents 13 Ordinary Shares.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $380.00 to $380.765, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $381.115 to $381.88, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Remarks:
/s/ Qing Nian, as Attorney-in-Fact 11/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BeOne Medicines (ONC) report in this Form 4?

The President and COO of BeOne Medicines Ltd. (ONC) reported sales of American Depositary Shares on 11/17/2025 in three open-market transactions.

How many BeOne Medicines ADS were sold and at what prices?

The filing reports sales of 3,155 ADS at a weighted average price of $380.2274, 826 ADS at a weighted average price of $381.1891, and 10 ADS at $382.32, all on 11/17/2025.

What BeOne Medicines securities does the insider report owning after the transaction?

The reporting person lists direct ownership of 968,978 ordinary shares and indirect ownership of 4,000 ADS held by his wife, in addition to the reduced direct ADS position shown after the sales.

What is the relationship between BeOne Medicines ADS and ordinary shares?

Each American Depositary Share of BeOne Medicines represents 13 ordinary shares, as disclosed in the explanation of responses.

Who is the reporting person in this BeOne Medicines (ONC) Form 4?

The reporting person is an officer of BeOne Medicines Ltd., serving as President and COO, and filed individually as one reporting person.

How were the BeOne Medicines ADS sale prices determined in this filing?

For the 3,155 and 826 ADS sales, the Form 4 notes that the prices shown are weighted average prices for multiple trades within stated ranges, and detailed trade data is available upon request.